Literature DB >> 9723691

B cell-mediated down-regulation of IFN-gamma and IL-12 production induced during anti-tumor immune responses in the tumor-bearing state.

R Wijesuriya1, S Maruo, J P Zou, M Ogawa, K Umehara, M Yamashita, S Ono, H Fujiwara, T Hamaoka.   

Abstract

Unfractionated spleen cells taken from tumor-bearing mice contained tumor-primed T cells which produced lymphokines such as IFN-gamma and IL-2 through collaboration with antigen-presenting cells (APC) binding tumor antigens when cultured in vitro. Here, we investigated the regulatory mechanisms underlying IFN-gamma production by T-APC interactions. Elimination of B cells from a splenic population of tumor-bearing mice resulted in enhanced IFN-gamma production. Adding B cells back into cultures down-regulated IFN-gamma production to almost the same levels as those induced by unfractionated spleen cells. IL-2 production was not enhanced by B cell depletion, but rather was significantly suppressed. IFN-gamma-selective up-regulation was due to an enhancement of IL-12 production because IL-12 was detected in B cell-depleted cultures and enhanced IFN-gamma production was prevented by addition of anti-IL-12 mAb or anti-CD40 ligand (CD40L) mAb capable of inhibiting CD40L-induced IL-12 production. These results indicate that B cells interfere with IFN-gamma production induced through interactions between anti-tumor T cells and APC, and this suppressive effect is based on the capacity of CD40+ B cells to down-regulate the CD40L-induced IL-12 production by APC.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9723691     DOI: 10.1093/intimm/10.8.1057

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  9 in total

1.  Circulating immunoglobulin-bound transforming growth factor beta at a late tumour-bearing stage impairs antigen-specific responses of CD4+ T cells.

Authors:  M Harada; K Tatsugami; M Nomoto; K Nomoto
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

2.  Promotion of tumor invasion by cooperation of granulocytes and macrophages activated by anti-tumor antibodies.

Authors:  E Barbera-Guillem; K F May; J K Nyhus; M B Nelson
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

Review 3.  Multiple vaccinations: friend or foe.

Authors:  Sarah E Church; Shawn M Jensen; Christopher G Twitty; Keith Bahjat; Hong-Ming Hu; Walter J Urba; Bernard A Fox
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

Review 4.  Design of CD40 agonists and their use in growing B cells for cancer immunotherapy.

Authors:  Richard S Kornbluth; Mariusz Stempniak; Geoffrey W Stone
Journal:  Int Rev Immunol       Date:  2012-08       Impact factor: 5.311

5.  A novel function of B lymphocytes from normal mice to suppress autoimmunity in (NZB x NZW)F1 mice.

Authors:  S Ono; D Shao; S Yamada; Y Yang; M Yamashita; T Hamaoka
Journal:  Immunology       Date:  2000-05       Impact factor: 7.397

6.  Circulation of gut-preactivated naïve CD8+ T cells enhances antitumor immunity in B cell-defective mice.

Authors:  Maryam Akrami; Rosemary Menzies; Kenji Chamoto; Michio Miyajima; Ryuji Suzuki; Hiroyuki Sato; Akiko Nishii; Michio Tomura; Sidonia Fagarasan; Tasuku Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-09       Impact factor: 11.205

Review 7.  Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity.

Authors:  David G DeNardo; Pauline Andreu; Lisa M Coussens
Journal:  Cancer Metastasis Rev       Date:  2010-06       Impact factor: 9.264

8.  Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein.

Authors:  C T Siegel; K Schreiber; S C Meredith; G B Beck-Engeser; D W Lancki; C A Lazarski; Y X Fu; D A Rowley; H Schreiber
Journal:  J Exp Med       Date:  2000-06-05       Impact factor: 14.307

9.  Role of ATP as a Key Signaling Molecule Mediating Radiation-Induced Biological Effects.

Authors:  Shuji Kojima; Yasuhiro Ohshima; Hiroko Nakatsukasa; Mitsutoshi Tsukimoto
Journal:  Dose Response       Date:  2017-02-15       Impact factor: 2.658

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.